The validation step in Rgs16::GFP mice is quantitative, cost effective, and rapid—10 min per mouse to quantitate tumor burden following a 2 week in vivo assay prior to weaning in a spontaneous model of PDA in transgenic mice. This evidence concerns the gene RGS16 and Patent ductus arteriosus.